Valion Bio (VBIO) Total Non-Current Liabilities (2024 - 2026)

Valion Bio has reported Total Non-Current Liabilities for 3 years, with the latest figure at $20.1 million in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $20.1 million in Q2 2026; TTM through Jun 2026 was $20.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $7.1 million, up 2527.94% from the prior year.
• Total Non-Current Liabilities was $20.1 million for Q2 2026 at Valion Bio, up from $7.1 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $20.1 million in Q2 2026, with the low at $272000.0 in Q4 2024.
• Average Total Non-Current Liabilities over 3 years is $9.2 million, with a median of $7.1 million recorded in 2025.
• The largest YoY upside for Total Non-Current Liabilities was 2527.94% in 2025 against a maximum downside of 2527.94% in 2025.
• Over 3 years, Total Non-Current Liabilities stood at $272000.0 in 2024, then soared by 2527.94% to $7.1 million in 2025, then surged by 181.67% to $20.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $20.1 million (Q2 2026), $7.1 million (Q4 2025), and $272000.0 (Q4 2024), per Business Quant data.